Eliyahou Harari, et al.
Known title: 10% OwnerCIK: 0001009165
Eliyahou Harari, et al.'s purchase track record
Eliyahou Harari, et al. has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/18/2026 | CV | $10.00M | pending | pending | — |
| 7/17/2026 | CV | $411K | -2.6% | pending | — |
| 7/8/2026 | CV | $495K | +6.8% | pending | — |
| 6/26/2026 | CV | $102K | -11.6% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CV | ▲ Buy | Open Market | 878,735 | $5.0M | 9/18/2026 | View on chart |
| CV | ▲ Buy | Open Market | 878,734 | $5.0M | 9/18/2026 | View on chart |
| CV | ▲ Buy | Open Market | 61,068 | $411K | 7/17/2026 | View on chart |
| CV | ▲ Buy | Open Market | 81,300 | $495K | 7/8/2026 | View on chart |
| CV | ▲ Buy | Open Market | 13,850 | $102K | 6/26/2026 | View on chart |
| CV | ▼ Sell | Other | 3,186,904 | — | 7/3/2025 | View on chart |
| CV | ▼ Sell | Other | 517,759 | — | 7/3/2025 | View on chart |
| CV | ▼ Sell | Other | 517,759 | — | 7/3/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CapsoVision Receives FDA Clearance for AI Highlights Tool
CapsoVision has secured FDA clearance for its AI Highlights reading tool on the CapsoCam Plus system. The approval allows the company to market the feature as a medical device, potentially expanding its use in clinical settings. The clearance may enhance the product’s value proposition and support future growth.
CapsoVision Receives FDA Clearance for AI Highlights Tool. CapsoVision has secured FDA clearance for its AI Highlights reading tool on the CapsoCam Plus system. The approval allows the company to market the feature as a medical device, potentially expanding its use in clinical settings. The clearance may enhance the product’s value proposition and support future growth.